<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0185-3325</journal-id>
<journal-title><![CDATA[Salud mental]]></journal-title>
<abbrev-journal-title><![CDATA[Salud Ment]]></abbrev-journal-title>
<issn>0185-3325</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0185-33252025000600307</article-id>
<article-id pub-id-type="doi">10.17711/sm.0185-3325.2025.035</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Aripiprazole versus Brexpiprazole for People with Schizophrenia: A Systematic Review]]></article-title>
<article-title xml:lang="es"><![CDATA[Aripiprazol versus brexpiprazol para personas con esquizofrenia: Revisión Sistemática]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores Medina]]></surname>
<given-names><![CDATA[Yvonne]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosel Vales]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escamilla Orozco]]></surname>
<given-names><![CDATA[Raúl Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saracco-Alvarez]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerrero Medrano]]></surname>
<given-names><![CDATA[Andrea Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Celada Borja]]></surname>
<given-names><![CDATA[Cesar Augusto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tiburcio Sainz]]></surname>
<given-names><![CDATA[Marcela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Vélez]]></surname>
<given-names><![CDATA[Nora Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Departamento de Servicios Clínicos ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Dirección de Investigaciones en Neurociencias ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Departamento de Investigaciones Epidemiológicas y Sociales ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,The Cochrane Collaboration  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Bahrain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>48</volume>
<numero>6</numero>
<fpage>307</fpage>
<lpage>316</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0185-33252025000600307&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0185-33252025000600307&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0185-33252025000600307&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction Schizophrenia is a chronic, complex, and multifactorial psychiatric disorder characterized by various clinical manifestations. The first line of treatment for this condition is antipsychotics. Second-generation antipsychotics use partial agonist mechanisms of D2 receptors that regulate dopaminergic tone, presumably reducing the incidence of extrapyramidal symptoms. Two second-generation molecules that have shown adequate efficacy for the treatment of positive symptoms in schizophrenia are aripiprazole and brexpiprazole and there are reviews comparing their effectiveness and safety in treatments of up to four weeks.  Objective To evaluate the efficacy and tolerability of aripiprazole compared with brexpiprazole in people diagnosed with schizophrenia or schizophrenia-like psychosis in medium- and long-term treatments.  Method The search was conducted by a specialist from the Cochrane schizophrenia group on March 9, 2023, in the MEERKAT registry, for (*Aripiprazole* and *Brexpiprazole*).  Results A total of 166 registers were identified from the electronic searches. Fifteen were eliminated due to duplication. The titles and abstracts of 151 records were examined, and four full texts were retrieved and assessed for eligibility according to inclusion and exclusion criteria. During this process, three studies were excluded, and finally only one study met the criteria for inclusion in this review.  Discussion and conclusion A single study was found to show data on efficacy, safety, and tolerability in patients with medium-term treatments. Since the evidence identified contains significant biases, it is not possible to establish a recommendation favoring the prescription of one of the antipsychotics in the study over the other.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción La esquizofrenia es un trastorno psiquiátrico crónico, complejo y multifactorial con diferentes manifestaciones clínicas. La primera línea de tratamiento para esta condición son los antipsicóticos, los de segunda generación utilizan mecanismos de acción con agonismo parcial de los receptores D2 que regulan el tono dopaminérgico, presumiblemente reduciendo la incidencia de síntomas extrapiramidales. Dos moléculas de segunda generación que han mostrado adecuada eficacia para el tratamiento de los síntomas positivos en esquizofrenia son el aripiprazol y el brexpiprazol y existen revisiones que comparan su efectividad y seguridad en tratamientos de hasta 4 semanas.  Objetivo Evaluar la eficacia y tolerabilidad del aripiprazol en comparación con el brexpiprazol en personas diagnosticadas con esquizofrenia o psicosis similar a la esquizofrenia en tratamientos de mediano y largo plazo.  Método La búsqueda se realizó en el registro MEERKAT, (*Aripiprazol* y *Brexpiprazol*) por un especialista del grupo Cochrane de esquizofrenia el 9 de marzo de 2023.  Resultados Se identificaron 166 registros a partir de las búsquedas electrónicas. Se eliminaron 15 por duplicación. Se examinaron los títulos y resúmenes de 151 registros, se recuperaron cuatro textos completos, &#64257;nalmente solo un estudio cumplió los criterios para ser incluido en esta revisión.  Discusión y conclusión Un solo estudio muestra datos sobre la eficacia, seguridad y tolerabilidad en pacientes con tratamientos de mediano plazo. La evidencia identificada muestra sesgos importantes, por lo que no es posible establecer una recomendación que favorezca la prescripción de uno de los antipsicóticos del estudio sobre el otro.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Brexpiprazole]]></kwd>
<kwd lng="en"><![CDATA[aripripazole]]></kwd>
<kwd lng="en"><![CDATA[schizophrenia]]></kwd>
<kwd lng="en"><![CDATA[systematic review]]></kwd>
<kwd lng="es"><![CDATA[Brexpiprazol]]></kwd>
<kwd lng="es"><![CDATA[aripripazol]]></kwd>
<kwd lng="es"><![CDATA[esquizofrenia]]></kwd>
<kwd lng="es"><![CDATA[revisión sistemática]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bazrafshan]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zare]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bazrafshan]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Zare]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Mazhari]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brexpiprazole versus placebo for people with schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2017</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belgamwar]]></surname>
<given-names><![CDATA[R. B.]]></given-names>
</name>
<name>
<surname><![CDATA[El-Sayeh]]></surname>
<given-names><![CDATA[H. G. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole versus placebo for schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2011</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhattacharjee]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[El-Sayeh]]></surname>
<given-names><![CDATA[H. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole versus typical antipsychotic drugs for schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2008</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Geddes]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole alone or in combination for acute mania]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2013</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Citrome]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out]]></article-title>
<source><![CDATA[International Journal of Clinical Practice]]></source>
<year>2015</year>
<volume>69</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1211-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Citrome]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ota]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagamizu]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Weiller]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia]]></article-title>
<source><![CDATA[International Clinical Psychopharmacology]]></source>
<year>2016</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>192-201</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Citrome]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ota]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagamizu]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Weiller]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of acute schizophrenia in adult patients using either brexpiprazole (OPC-34712) or aripiprazole, an exploratory study]]></article-title>
<source><![CDATA[CNS Spectrums]]></source>
<year>2016</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-121</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Citrome]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ota]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagamizu]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Weiller]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: An exploratory study]]></article-title>
<source><![CDATA[Biological Psychiatry]]></source>
<year>2015</year>
<volume>77</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Citrome]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ota]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagamizu]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Weiller]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brexpiprazole (OPC-34712) vs aripiprazole in adults with acute schizophrenia: A multicenter, randomized, open-label, flexible-dose, exploratory study]]></article-title>
<source><![CDATA[European Neuropsychopharmacology]]></source>
<year>2015</year>
<volume>2</volume>
<numero>^s516</numero>
<issue>^s516</issue>
<supplement>516</supplement>
<page-range>517-10.1097/YIC.0000000000000123</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correll]]></surname>
<given-names><![CDATA[C. U.]]></given-names>
</name>
<name>
<surname><![CDATA[Schooler]]></surname>
<given-names><![CDATA[N. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment]]></article-title>
<source><![CDATA[Neuropsychiatric Disease and Treatment]]></source>
<year>2020</year>
<volume>16</volume>
<page-range>519-34</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Sayeh]]></surname>
<given-names><![CDATA[H. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Morganti]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole for schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2006</year>
<volume>2</volume>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frankel]]></surname>
<given-names><![CDATA[J. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[T. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole]]></article-title>
<source><![CDATA[Therapeutic Advances in Psychopharmacology]]></source>
<year>2017</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-41</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GRADEpro G.]]></surname>
<given-names><![CDATA[D. T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Computer program. McMaster University]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Falkai]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Lehmann]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Gaebel]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Schizophrenia]]></article-title>
<source><![CDATA[Deutsches Ärzteblatt International]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hey]]></surname>
<given-names><![CDATA[S. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Kimmelman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The questionable use of unequal allocation in confirmatory trials]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2014</year>
<volume>82</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Savovi&#263;]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Elbers]]></surname>
<given-names><![CDATA[R. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Sterne]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing risk of bias in a randomized trial]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Chandler]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cumpston]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Welch]]></surname>
<given-names><![CDATA[V. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Handbook for Systematic Reviews of Interventions]]></source>
<year>2023</year>
<edition>205</edition>
<page-range>228-10.1002/9781119536604.ch8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[L. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Pringsheim]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole for autism spectrum disorders (ASD)]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2016</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huhn]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolakopoulou]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider-Thoma]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Krause]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Samara]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Peter]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Arndt]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Bäckers]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Rothe]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Cipriani]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Salanti]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Leucht]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2019</year>
<volume>394</volume>
<numero>10202</numero>
<issue>10202</issue>
<page-range>939-51</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Suo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Komossa]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Rummel-Kluge]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[El-Sayeh]]></surname>
<given-names><![CDATA[H. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Leucht]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole versus other atypical antipsychotics for schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2014</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kikuchi]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hirose]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Futamura]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[McQuade]]></surname>
<given-names><![CDATA[R. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole]]></article-title>
<source><![CDATA[Neuropsychopharmacology Reports]]></source>
<year>2021</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-43</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kishi]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Ikuta]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuda]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Sakuma]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Iwata]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2020</year>
<volume>237</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1459-70</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Vélez]]></surname>
<given-names><![CDATA[N. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Escamilla Orozco]]></surname>
<given-names><![CDATA[R. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Flores Medina]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Saracco-Alvarez]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosel Vales]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Salas]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Hernández]]></surname>
<given-names><![CDATA[G. Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole versus brexpiprazole for people with schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2023</year>
<volume>2</volume>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCutcheon]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Reis Marques]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Howes]]></surname>
<given-names><![CDATA[O. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Schizophrenia&#8212;An Overview]]></article-title>
<source><![CDATA[JAMA Psychiatry]]></source>
<year>2020</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mihaljevi&#263;-Pele&#353;]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bajs Janovi&#263;]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[&#352;agud]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[&#381;ivkovi&#263;]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Janovi&#263;]]></surname>
<given-names><![CDATA[&#352;.]]></given-names>
</name>
<name>
<surname><![CDATA[Jevtovi&#263;]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognitive deficit in schizophrenia: an overview]]></article-title>
<source><![CDATA[Psychiatria Danubina]]></source>
<year>2019</year>
<volume>31</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>139-42</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Millier]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Angermeyer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Chauhan]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Murthy]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Toumi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cadi-Soussi]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Humanistic burden in schizophrenia: A literature review]]></article-title>
<source><![CDATA[Journal of Psychiatric Research]]></source>
<year>2014</year>
<volume>54</volume>
<page-range>85-93</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostinelli]]></surname>
<given-names><![CDATA[E. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Jajawi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Spyridi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sayal]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Jayaram]]></surname>
<given-names><![CDATA[M. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2018</year>
<volume>1</volume>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owen]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sawa]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mortensen]]></surname>
<given-names><![CDATA[P. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Schizophrenia]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10039</numero>
<issue>10039</issue>
<page-range>86-97</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ralovska]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Koychev]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Marinov]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Furukawa]]></surname>
<given-names><![CDATA[T. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mulsant]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Cipriani]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brexpiprazole versus placebo or other antidepressive agents for treating depression]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2023</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="">
<collab>The Cochrane Collaboration</collab>
<source><![CDATA[Review Manager Web]]></source>
<year>2023</year>
<edition>6.1.0.</edition>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schünemann]]></surname>
<given-names><![CDATA[H. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Vist]]></surname>
<given-names><![CDATA[G. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Glasziou]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Akl]]></surname>
<given-names><![CDATA[E. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Skoetz]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[G.H.]]></given-names>
</name>
</person-group>
<collab>Cochrane GRADEing Methods Group (formerly Applicability and Recommendations Methods Group) Cochrane Statistical Methods Group</collab>
<article-title xml:lang=""><![CDATA[Completing &#8216;Summary of findings&#8217; tables and grading the certainty of the evidence]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Thoma]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Chandler]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cumpston]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Welch]]></surname>
<given-names><![CDATA[V. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Handbook for Systematic Reviews of Interventions]]></source>
<year>2023</year>
<page-range>375-402</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sommer]]></surname>
<given-names><![CDATA[I. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Tiihonen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[van Mourik]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Tanskanen]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Taipale]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical course of schizophrenia in women and men&#8212;a nation-wide cohort study.npj]]></article-title>
<source><![CDATA[npj Schizophrenia]]></source>
<year>2020</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[S. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanism of action of brexpiprazole: comparison with aripiprazole.]]></article-title>
<source><![CDATA[CNS Spectrums]]></source>
<year>2016</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Citrome]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy]]></article-title>
<source><![CDATA[Neuropsychiatric Disease and Treatment]]></source>
<year>2019</year>
<volume>15</volume>
<page-range>247-57</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
